CRISPR Gene Editing Explained Simply: Cas9, PAM and Uses

CRISPR gene editing cuts DNA at a chosen location using a Cas enzyme guided by a short RNA, then relies on the cell's own repair machinery to change the sequence. The system was borrowed from bacteria, which use it to recognise and destroy viral DNA, and it made targeted editing far faster and cheaper than earlier tools such as zinc finger nucleases and TALENs.

In molecular biology and diagnostics labs, CRISPR is now everyday vocabulary. Knowing how it works, and where it goes wrong, helps you read papers critically and plan experiments safely.

Where CRISPR comes from: a bacterial immune system

CRISPR stands for clustered regularly interspaced short palindromic repeats. In bacterial and archaeal genomes these repeats are separated by short spacers, many matching bacteriophages and plasmids the cell has met before. When an invader returns, the cell transcribes the array into CRISPR RNAs that guide Cas (CRISPR-associated) proteins to the matching foreign DNA, which is then cut. It is an adaptive immune memory written into the genome.

In 2012, Emmanuelle Charpentier, Jennifer Doudna and colleagues showed that Cas9 from Streptococcus pyogenes could be programmed with a single engineered guide RNA to cut a chosen DNA sequence. Charpentier and Doudna received the 2020 Nobel Prize in Chemistry for developing the method.

How Cas9, the guide RNA and the PAM work

• Cas9 nuclease: the enzyme that cuts both strands of DNA.
• Guide RNA (gRNA): usually a single guide RNA carrying a spacer of about 20 nucleotides that base-pairs with the target, plus a scaffold that binds Cas9.

Cas9 cannot cut just anywhere. It first looks for a short protospacer adjacent motif (PAM) next to the target. For the widely used S. pyogenes Cas9 (SpCas9) the PAM is 5'-NGG-3', where N is any base. Only when a PAM is present and the guide matches does Cas9 make a double-strand break (DSB), about three bases upstream of the PAM.

PAM availability limits where you can edit, so engineered Cas9 variants and other enzymes such as Cas12a, which recognises a T-rich PAM, are used to widen the choice.

Repairing the cut: NHEJ vs HDR

• Non-homologous end joining (NHEJ): the dominant, error-prone pathway, which often inserts or deletes a few bases (indels). An indel in a coding exon that is not a multiple of three causes a frameshift, which is how most gene knockouts are made.
• Homology-directed repair (HDR): copies a precise change, such as a point mutation or tag, from a supplied donor template. It is much less efficient than NHEJ and works mainly in dividing cells.

Base editing, prime editing and a comparison table

Double-strand breaks can cause unwanted large deletions or rearrangements, so newer tools avoid them. Base editors, first described in 2016, fuse a Cas9 nickase (which cuts one strand) to a deaminase: cytosine base editors convert C•G to T•A and adenine base editors convert A•T to G•C. Prime editors, first described in 2019, fuse a Cas9 nickase to a reverse transcriptase and use a pegRNA that carries the new sequence, allowing all 12 single-base substitutions plus small insertions and deletions.

Applications: research, agriculture, diagnostics and therapy

Research: knockouts and genome-wide CRISPR screens let labs test gene function in cell lines and model organisms in weeks rather than months.

Agriculture: editing can give crops traits such as disease resistance, often by knocking out a gene without adding foreign DNA. Regulation differs between countries, and some, including India, treat certain edits without foreign DNA differently from conventional GMOs, so check current national rules.

Diagnostics: activated Cas12 and Cas13 enzymes cut nearby reporter molecules indiscriminately (collateral cleavage). SHERLOCK uses Cas13 to detect RNA and DETECTR uses Cas12a to detect DNA, usually after isothermal amplification. They complement methods such as qPCR, and clinical use needs validation and regulatory authorisation.

Therapy: in November 2023, the UK regulator (MHRA) authorised Casgevy (exagamglogene autotemcel), the first CRISPR-based medicine, for sickle cell disease and transfusion-dependent beta-thalassaemia. The US FDA approved it for sickle cell disease in December 2023. The patient's own blood stem cells are edited outside the body to reactivate fetal haemoglobin production, then returned after chemotherapy conditioning, an ex vivo cell and gene therapy.

Off-target effects and ethics

A guide RNA can tolerate some mismatches, so Cas9 may cut similar sequences elsewhere. Labs reduce this risk with careful guide selection, high-fidelity Cas9 variants, short-lived ribonucleoprotein (RNP) delivery rather than plasmids, and sequencing of top predicted off-target sites.

The sharpest ethical debate concerns germline editing, which changes embryos, eggs or sperm so edits pass to future generations. In 2018, He Jiankui announced the birth of twin girls whose embryos had been edited at the CCR5 gene. The work was condemned internationally and he was later convicted in China. Heritable human genome editing is not permitted for clinical use in many countries; somatic editing, affecting only the treated patient, follows normal clinical trial regulation.

Worked example: designing a knockout in a Bengaluru research lab

A university cell biology lab in Bengaluru wants to knock out a gene suspected of driving drug resistance in a human cancer cell line. The plan:

1. Target: an early coding exon shared by all known transcripts, so a frameshift disrupts every isoform.
2. Guides: three guides next to NGG PAM sites, ranked by predicted activity and fewest close off-target matches.
3. Approvals: confirm institutional biosafety committee cover and the lab risk assessment.
4. Delivery: electroporate Cas9 RNP, with a non-targeting guide as the negative control.
5. Editing check: PCR-amplify the site and analyse by Sanger sequencing with decomposition software, or by amplicon sequencing.
6. Clones: expand single-cell clones, confirm frameshifts on every allele and confirm protein loss by Western blot.
7. Final checks: sequence top off-target sites, authenticate the cell line and test for mycoplasma.

The team keeps two knockout clones made with different guides. Matching results from both are far more convincing than one clone, which could carry an unrelated mutation.

Common mistakes

• Targeting a late exon, or one that alternative splicing can skip.
• Assuming an indel means the protein is gone, without a Western blot.
• Relying on one clone or one guide.
• Never sequencing high-risk off-target sites.
• Treating a mixed edited population as a clonal knockout.

Key takeaway: CRISPR-Cas9 uses a guide RNA and a PAM to make a targeted cut, and the cell's repair pathway decides the edit. Base and prime editors avoid double-strand breaks. Careful guide design, controls and off-target checks turn an edit into a reliable result.

Frequently Asked Questions

What does CRISPR stand for?

CRISPR stands for clustered regularly interspaced short palindromic repeats. These repeat sequences in bacterial and archaeal DNA are separated by spacers taken from viruses and plasmids, and together with Cas proteins they form an adaptive immune system. Scientists adapted this natural system into a programmable tool that can cut and edit DNA in almost any organism.

What is the difference between CRISPR and gene therapy?

CRISPR is a tool, while gene therapy is a treatment approach. Gene therapy covers any method that treats disease by changing genetic material, such as adding a working gene with a viral vector. CRISPR-based therapies are one type of gene therapy that edit the patient's existing DNA, for example Casgevy for sickle cell disease and beta-thalassaemia.

Is CRISPR gene editing safe?

Safety depends on the application. Known risks include off-target edits, unintended large deletions at the cut site and immune reactions to Cas proteins or delivery vectors. Approved therapies such as Casgevy went through clinical trials and regulatory review, and patients are followed up over the long term. Heritable germline editing is not considered safe or acceptable for clinical use.

What is a PAM sequence in CRISPR?

A PAM, or protospacer adjacent motif, is a short DNA sequence next to the target that the Cas enzyme must recognise before it can cut. For SpCas9 it is NGG. Without a nearby PAM, Cas9 will not cut even when the guide matches perfectly, so the position of PAM sites limits where you can edit.

Next steps

To go deeper into genome editing and advanced therapies, explore our Frontier Biotechnology: Genome Editing, Advanced Therapies and AI course. To analyse editing outcomes and sequencing data yourself, Bioinformatics and Genomics Essentials is a practical start.

Related reading: next-generation sequencing explained, cell and gene therapy basics and careers in microbiology and biotechnology. Not sure where to begin? Speak to a counsellor.